Abstract 118P
Background
Recently, anti-PD-1/L1 plus gemcitabine and cisplatin (GemCis) has demonstrated significant survival benefits in randomized phase 3 trials for advanced BTC. However, no biomarker has been established for anti-PD-1 in BTC. Here, we assessed TILs using artificial intelligence (AI)-powered spatial analysis in advanced BTC treated with anti-PD-1.
Methods
An AI-powered whole-slide image (WSI) analyzer (Lunit SCOPE IO, Lunit, Seoul, Korea) was used to segment tumor epithelium and stroma, and identification of intratumor TIL (iTIL) and stromal TIL (sTIL). H&E-stained WSI from pre-treatment samples was acquired from Asan Medical Center and Yonsei Cancer Center (n = 354), and a total of 337 samples (95.2%) after quality control were used for the final analysis. Immune phenotypes (IP) were defined as follows: inamed as high iTIL and sTIL; immune-excluded as low iTIL and high sTIL; immune-desert as low TIL overall. Among them, 29 patients (pts) were available for multi-color flow cytometry analysis (FACS) using peripheral blood mononuclear cells (PBMC), collected at baseline and C1D8.
Results
All patients were treated with anti-PD-1 monotherapy, and 188 pts (55.8%) were treated as 2nd line. In overall pts, anti-PD-1 showed median overall survival (OS) of 5.7 months (mo), median progression-free survival (PFS) of 2.0 mo, and objective response rates (ORR) of 10.1%. IP were classified as inflamed in 40 pts (11.9%), immune-excluded in 167 (49.6%), and immune-desert in 130 (38.6%). The inflamed group showed better OS (12.5 vs. 5.1 mo, P<0.001), PFS (5.0 vs. 2.0 mo, P=0.001), and ORR (27.5% vs. 7.7%, P<0.001) than non-inflamed groups. In the FACS, the inflamed group showed significantly higher proportion of baseline CD8+Tem and lower baseline CD8+Tnaive than non-inflamed groups. At C1D8 of anti-PD-1, CD69+CD8+T, GZMB+CD8+T, and PRF1+CD8+T cells were increased, while PD1+CD8+T cells was decreased in PBMC of the inflamed group.
Conclusions
Immune phenotype classified by AI-powered spatial TIL analysis was effective to predict the efficacy outcomes of advanced BTC pts treated with anti-PD-1 therapy. Further evaluation is required in the setting of anti-PD-1/L1 plus GemCis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Ock: Financial Interests, Institutional, Advisory Board: Lunit corporate. All other authors have declared no conflicts of interest.
Resources from the same session
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17
689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Presenter: Omkar Marathe
Session: Poster session 17